Skip to main content

Market Overview

Intercept Pharmaceutical Shares Skyrocket after Oppenheimer's Data "Optimism"


Shares of Intercept Pharmaceuticals (NASDAQ: ICPT) have skyrocketed after Oppenheimer analyst Akiva commented on data “optimism” ahead of Phase 3 PBC data in 2Q14.

Akiva noted the buying opportunity for Intercept following the recent pull-back. Oppenheimer spoke with the company and reported that the majority of patients have completed their dose of POISE with the last patient completing their dose by the end of the year. The analyst commented that S-1 filing and Form 4 selling confusion may be key factors contributing to the weakness of shares.

The AASLD symposium will be focused on PBC awareness. Intercept Pharmaceuticals expects to report Phase 2a PH (PESTO) and BAD (OBADIAH) data by year end.

Oppenheimer $94 PT remains high compared to Bloomberg's average of $75.

Intercept Pharmaceuticals closed at $54.96 on Wednesday and is currently trading +8.84 percent.


Related Articles ((NASDAQ: + ICPT))

View Comments and Join the Discussion!

Posted-In: Akiva OppenheimerAnalyst Color News Rumors Analyst Ratings

Latest Ratings

NUAGRoth CapitalUpgrades6.5
FRCCredit SuisseMaintains163.0
WRAPMaxim GroupInitiates Coverage On11.0
FRTDeutsche BankMaintains113.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at